Nanoparticle delivered miR-489 rejuvenates anthracycline-based chemotherapy
纳米颗粒递送的 miR-489 使基于蒽环类药物的化疗恢复活力
基本信息
- 批准号:10044059
- 负责人:
- 金额:$ 18万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-06-01 至 2022-05-30
- 项目状态:已结题
- 来源:
- 关键词:AnthracyclineApoptosisAutophagocytosisBreast Cancer PatientCell DeathCell LineCell NucleusCell ProliferationCellsCessation of lifeClinicalDataDevelopmentDistant MetastasisDoxorubicinDrug resistanceDrug resistance pathwayERBB2 geneEncapsulatedEpithelialEpitheliumFilmGenesGoalsHormonesHydration statusImmune responseImmunotherapyIn VitroLeadMalignant NeoplasmsMammary NeoplasmsMaximum Tolerated DoseMesenchymalMethodsMicroRNAsMolecularPathway interactionsPatient-derived xenograft models of breast cancerPatientsPharmaceutical PreparationsPrimary NeoplasmPublishingQuality of lifeRecurrenceRegimenResistanceRiskSignal PathwaySystemTestingTherapeuticTherapeutic AgentsThinnessTissue HarvestingToxic effectTumor ImmunityXenograft ModelXenograft procedureanti-cancerbasechemotherapycytotoxicdosageendoplasmic reticulum stresshormone therapyhumanized mouseimprovedin vivoinhibitor/antagonistmalignant breast neoplasmmouse modelnanoparticlenanoparticle deliverynovelnovel therapeuticsrestorationsuccesstargeted treatmenttaxanetooltriple-negative invasive breast carcinomatumortumor growth
项目摘要
Abstract
Triple-negative breast cancer (TNBC) comprises 15 to 20% of breast cancers and is the most
aggressive subtype with a significantly shorter median overall survival compared to other subtypes.
There are no targeted therapies for TNBC and only 10% of TNBC patients respond to immune therapy.
Thus, most of patients with TNBC still mainly depend on conventional chemotherapies, with doxorubicin
(Dox) as a commonly used one. The two crucial concerns with use of chemotherapies such as Dox are
severe toxicity and drug resistance. Extensive studies have unveiled many altered signaling pathways
that contribute to the development of Dox resistance. However, it is a daunting task to identify agents
that can target the diverse drug-resistant pathways simultaneously. Recently, synthetic miRNA mimics
or inhibitors have become attractive tools to battle cancer as a new type of therapies or to break drug
resistance because one microRNA can target multiple genes in multiple signaling pathways. Our recent
published data showed that miR-489 is lost in a majority of breast cancers especially TNBC. Loss of
miR-489 confers resistance to chemotherapies such as doxorubicin (Dox) and restoration of miR-489
reverses Dox resistance both in vitro and in vivo. Further mechanistic studies revealed that miR489
can inhibit Dox-induced cytoprotective autophagy, increase Dox localization in nucleus and potentiate
Dox-induced ATP release. Importantly, we developed a nanoparticle system to specifically deliver
miR489 to breast tumors. Based on these findings, we propose that nanoparticle delivered miR-489
can simultaneously modulate multiple pathways involved in cell proliferation, apoptosis, epithelial-
mesenchymal transition (EMT), autophagy and ER stress to enhance Dox-induced cell death and anti-
cancer immunity and therefore delay or reverse Dox resistance. Three specific aims are proposed.
SA1. To formulate tumor-targeting miR-489 nanoparticles and characterize the delivery efficiency and
toxicity both in vitro and in vivo. SA2. To test whether miR-489 synergizes with Dox to induce cell
death and reverses Dox-resistance using cell line and patient-derived xenograft (PDX) mouse models.
SA3. To investigate whether miR-489 enhances the efficacy of Dox treatment of PDX using humanized
mouse models. Overall, this study aims to develop miR-489 as a novel therapeutic agent to reverse
Dox resistance and thus enhance the efficacy of Dox-based chemotherapy.
摘要
三阴性乳腺癌(TNBC)占乳腺癌的15%至20%,是最常见的乳腺癌。
与其他亚型相比,侵袭性亚型的中位总生存期显著较短。
TNBC没有靶向治疗,只有10%的TNBC患者对免疫治疗有反应。
因此,大多数TNBC患者仍主要依赖常规化疗,其中多柔比星
(Dox)作为一种常用的。使用Dox等化疗药物的两个关键问题是
严重的毒性和耐药性。广泛的研究揭示了许多改变的信号通路
导致对多柔比星耐药性的发展。然而,要确定代理人是一项艰巨的任务
可以同时针对不同的耐药途径。最近,合成的miRNA模拟物
或抑制剂已成为有吸引力的工具,以对抗癌症作为一种新型疗法或打破药物
因为一个microRNA可以靶向多个信号通路中的多个基因。我们最近
公开的数据显示,miR-489在大多数乳腺癌尤其是TNBC中丢失。损失
miR-489赋予对化疗如阿霉素(Dox)的抗性和miR-489的恢复
在体外和体内逆转Dox抗性。进一步的机制研究表明,miR 489
可抑制Dox诱导的细胞保护性自噬,增加Dox在细胞核中的定位,
Dox诱导的ATP释放。重要的是,我们开发了一种纳米颗粒系统,
miR 489用于乳腺肿瘤。基于这些发现,我们建议纳米颗粒递送miR-489
可以同时调节细胞增殖、凋亡、上皮细胞增殖、细胞凋亡和细胞凋亡等多种途径。
间充质转化(EMT),自噬和ER应激,以增强Dox诱导的细胞死亡和抗
癌症免疫力,因此延迟或逆转Dox抗性。提出了三个具体目标。
SA 1.为了配制肿瘤靶向miR-489纳米颗粒并表征递送效率,
体外和体内毒性。SA 2.为了测试miR-489是否与Dox协同诱导细胞凋亡,
使用细胞系和患者来源的异种移植(PDX)小鼠模型,
SA 3.为了研究miR-489是否增强使用人源化miR-489的PDX的Dox治疗的功效,
小鼠模型。总的来说,这项研究的目的是开发miR-489作为一种新的治疗剂,以逆转
Dox耐药性,从而增强基于Dox的化疗的疗效。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Hexin Chen其他文献
Hexin Chen的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Hexin Chen', 18)}}的其他基金
HER2 and the link between inflammation and cancer stem cells
HER2 以及炎症和癌症干细胞之间的联系
- 批准号:
8717617 - 财政年份:2013
- 资助金额:
$ 18万 - 项目类别:
HER2 and the link between inflammation and cancer stem cells
HER2 以及炎症和癌症干细胞之间的联系
- 批准号:
8562650 - 财政年份:2013
- 资助金额:
$ 18万 - 项目类别:
相似国自然基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
- 批准号:LBY21H010001
- 批准年份:2020
- 资助金额:0.0 万元
- 项目类别:省市级项目
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
- 批准号:81703335
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
- 批准号:81670594
- 批准年份:2016
- 资助金额:58.0 万元
- 项目类别:面上项目
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
- 批准号:81470791
- 批准年份:2014
- 资助金额:73.0 万元
- 项目类别:面上项目
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
- 批准号:81301123
- 批准年份:2013
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
- 批准号:81101529
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
- 批准号:39500043
- 批准年份:1995
- 资助金额:9.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Development of an apoptosis biosensor for monitoring of breast cancer
开发用于监测乳腺癌的细胞凋亡生物传感器
- 批准号:
10719415 - 财政年份:2023
- 资助金额:
$ 18万 - 项目类别:
Milk fat globule-EGF factor 8 and hepatocyte apoptosis-induced liver wound healing response
乳脂肪球-EGF因子8与肝细胞凋亡诱导的肝脏创面愈合反应
- 批准号:
10585802 - 财政年份:2023
- 资助金额:
$ 18万 - 项目类别:
Interrogating the Fgl2-FcγRIIB axis on CD8+ T cells: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
询问 CD8 T 细胞上的 Fgl2-FcγRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
- 批准号:
10605856 - 财政年份:2023
- 资助金额:
$ 18万 - 项目类别:
Novel targeted therapy for FGFR inhibitor-resistant urothelial cancer and apoptosis based therapy for urothelial cancer
FGFR抑制剂耐药性尿路上皮癌的新型靶向治疗和基于细胞凋亡的尿路上皮癌治疗
- 批准号:
23K08773 - 财政年份:2023
- 资助金额:
$ 18万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Mechanistic analysis of apoptosis induction by HDAC inhibitors in head and neck cancer
HDAC抑制剂诱导头颈癌凋亡的机制分析
- 批准号:
23K15866 - 财政年份:2023
- 资助金额:
$ 18万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Interrogating the Fgl2-FcgRIIB axis: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
探究 Fgl2-FcgRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
- 批准号:
10743485 - 财政年份:2023
- 资助金额:
$ 18万 - 项目类别:
Investigating the role of apoptosis-resistance and the tumor environment on development and maintenance of sacrococcygeal teratomas
研究细胞凋亡抗性和肿瘤环境对骶尾部畸胎瘤发生和维持的作用
- 批准号:
10749797 - 财政年份:2023
- 资助金额:
$ 18万 - 项目类别:
The effects of glucose on immune cell apoptosis and mitochondrial membrane potential and the analysis of its mechanism by which glucose might modulate the immune functions.
葡萄糖对免疫细胞凋亡和线粒体膜电位的影响及其调节免疫功能的机制分析。
- 批准号:
22K09076 - 财政年份:2022
- 资助金额:
$ 18万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
XAF1 IN P53 SIGNALING, APOPTOSIS AND TUMOR SUPPRESSION
P53 信号传导、细胞凋亡和肿瘤抑制中的 XAF1
- 批准号:
10583516 - 财政年份:2022
- 资助金额:
$ 18万 - 项目类别:
Role of Thioredoxin system in regulation of autophagy-apoptosis cross talk in neurons: Uncovering Novel Molecular Interactions.
硫氧还蛋白系统在神经元自噬-凋亡串扰调节中的作用:揭示新的分子相互作用。
- 批准号:
RGPIN-2019-05371 - 财政年份:2022
- 资助金额:
$ 18万 - 项目类别:
Discovery Grants Program - Individual